103 related articles for article (PubMed ID: 3732352)
21. Serum hormone levels in breast cancer patients and controls in Egypt and Great Britain. The Anglo-Egyptian Health Agreement Collaborative Study.
Eur J Cancer Clin Oncol; 1988 Aug; 24(8):1329-35. PubMed ID: 3181253
[TBL] [Abstract][Full Text] [Related]
22. Increased hypothalamic dopaminergic tone only in early parous women with either malignant or benign breast tumors.
Ortega-González C; Parra A; Barra R; Aranda C; Ramírez D; Di Castro P; Castro I; Zambrana M; Coria I
Endocr Pract; 2002; 8(2):89-95. PubMed ID: 11942771
[TBL] [Abstract][Full Text] [Related]
23. A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer.
Tworoger SS; Eliassen AH; Sluss P; Hankinson SE
J Clin Oncol; 2007 Apr; 25(12):1482-8. PubMed ID: 17372279
[TBL] [Abstract][Full Text] [Related]
24. Prolactin concentrations in patients with breast cancer.
Franks S; Ralphs DN; Seagroatt V; Jacobs HS
Br Med J; 1974 Nov; 4(5940):320-1. PubMed ID: 4434088
[TBL] [Abstract][Full Text] [Related]
25. Plasma prolactin levels and breast cancer: relation to parity, weight and height, and age at first birth.
Kwa HG; Cleton F; Bulbrook RD; Wang DY; Hayward JL
Int J Cancer; 1981 Jul; 28(1):31-4. PubMed ID: 7309279
[TBL] [Abstract][Full Text] [Related]
26. Prolactin and growth hormone levels in premenopausal women with breast cancer and healthy women with a strong family history of breast cancer.
Love RR; Rose DR; Surawicz TS; Newcomb PA
Cancer; 1991 Sep; 68(6):1401-5. PubMed ID: 1873792
[TBL] [Abstract][Full Text] [Related]
27. Season of tumour detection influences factors predicting survival of patients with breast cancer.
Mason BH; Holdaway IM; Stewart AW; Neave LM; Kay RG
Breast Cancer Res Treat; 1990 Jan; 15(1):27-37. PubMed ID: 2328328
[TBL] [Abstract][Full Text] [Related]
28. Plasma lipids and prolactin in patients with breast cancer.
Bani IA; Williams CM; Boulter PS; Dickerson JW
Br J Cancer; 1986 Sep; 54(3):439-46. PubMed ID: 3756079
[TBL] [Abstract][Full Text] [Related]
29. HER2 expression in breast cancer: correlation with endocrine function and psychological status in operable and metastatic breast cancer.
Lissoni P; Messina G; Rovelli F; Brivio F; Fumagalli L; Villa S; Bartolacelli E
In Vivo; 2009; 23(6):987-9. PubMed ID: 20023245
[TBL] [Abstract][Full Text] [Related]
30. Prediction of recurrence in operable breast cancer by postoperative changes in prolactin secretion.
Lissoni P; Barni S; Cazzaniga M; Ardizzoia A; Rovelli F; Tancini G; Brivio F; Frigerio F
Oncology; 1995; 52(6):439-42. PubMed ID: 7478427
[TBL] [Abstract][Full Text] [Related]
31. Abnormalities in evening plasma prolactin levels in nulliparous women with benign or malignant breast disease.
Tarquini A; di Martino L; Malloci A; Kwa HG; van der Gugten AA; Bulbrook RD; Wang DY
Int J Cancer; 1978 Dec; 22(6):687-90. PubMed ID: 721323
[TBL] [Abstract][Full Text] [Related]
32. Relationship of blood prolactin levels and the risk of subsequent breast cancer.
Wang DY; De Stavola BL; Bulbrook RD; Allen DS; Kwa HG; Fentiman IS; Hayward JL; Millis RR
Int J Epidemiol; 1992 Apr; 21(2):214-21. PubMed ID: 1428472
[TBL] [Abstract][Full Text] [Related]
33. Postoperative hyperprolactinaemia and early recurrence rate in breast cancer.
Lissoni P; Sormani AL; Tancini G; Cattaneo G; Archili C; Mandelli D; Crispino S; Paolorossi F; Barni S
Eur J Cancer; 1990; 26(9):953-6. PubMed ID: 2149021
[TBL] [Abstract][Full Text] [Related]
34. Molecular Subtypes and Prognostic Factors among Premenopausal and Postmenopausal Thai Women with Invasive Breast Cancer: 15 Years Follow-up Data.
Tubtimhin S; Promthet S; Suwanrungruang K; Supaattagorn P
Asian Pac J Cancer Prev; 2018 Nov; 19(11):3167-3174. PubMed ID: 30486605
[TBL] [Abstract][Full Text] [Related]
35. Prolactin and breast cancer risk.
Ingram DM; Nottage EM; Roberts AN
Med J Aust; 1990 Oct; 153(8):469-73. PubMed ID: 2215338
[TBL] [Abstract][Full Text] [Related]
36. Poorer survival of nulliparous women with endometrial carcinoma.
Salvesen HB; Akslen LA; Albrektsen G; Iversen OE
Cancer; 1998 Apr; 82(7):1328-33. PubMed ID: 9529025
[TBL] [Abstract][Full Text] [Related]
37. Risk factors and 10-year breast cancer survival in northern Alberta.
Lees AW; Jenkins HJ; May CL; Cherian G; Lam EW; Hanson J
Breast Cancer Res Treat; 1989 Mar; 13(2):143-51. PubMed ID: 2730961
[TBL] [Abstract][Full Text] [Related]
38. Elevated levels of prolactin in nulliparous women.
Yu MC; Gerkins VR; Henderson BE; Brown JB; Pike MC
Br J Cancer; 1981 Jun; 43(6):826-31. PubMed ID: 7248160
[TBL] [Abstract][Full Text] [Related]
39. Haptoglobin-related protein (Hpr) epitopes in breast cancer as a predictor of recurrence of the disease.
Kuhajda FP; Piantadosi S; Pasternack GR
N Engl J Med; 1989 Sep; 321(10):636-41. PubMed ID: 2475778
[TBL] [Abstract][Full Text] [Related]
40. Disordered nocturnal prolactin regulation in women with breast cancer.
Malarkey WB; Schroeder LL; Stevens VC; James AG; Lanese RR
Cancer Res; 1977 Dec; 37(12):4650-4. PubMed ID: 922745
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
